🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

👉👉👉Meeting of the #hematology minds from MD Anderson Cancer Center at #ASCO25 ASCO Journal of Clinical Oncology | #leusm #MPNSM #BPDCN 🙌 #endcancer

Amazing day at #ASCO25 plenary session! First an #MPN abstract in the plenary! Second, amazing job by Andrew Kuykendall MD for presenting #VERIFY PhIII trial demonstrating Rusferatide impact on phlebotomy and PV symptoms in PV MPN World MPN Research Foundation Takeda MPN_Hub Moffitt Cancer Center

3rd Plenary #ASCO25: #VERIFY Ph III, Rufertide (subcutaneous, hepcidin mimetic) vs Placebo in phlebotomy dependent polycythemia vera. - Improved the need of phlebotomy. Hct control: 76.9% vs 32.9% - Improved symptoms/fatigue By: Drs. Andrew Kuykendall MD & Kathy Walsh, MD, MAEd

Such an amazing feeling when your role models/mentor travel for only few hours to ASCO to celebrate! For the heme crew on #ASCO2025 Dr. Barrientos was here 🙌🎉 Congratulations to Dr. Flowers on his award for Excellence on Teaching and Mentor Award 🏆 #Mentorship #education

3. #VERIFY: Ph III, Rufertide (subcutaneous, hepcidin mimetic) vs Placebo in phlebotomy dependent polycythemia vera. 4/6

Lovely to catch up with so many current members of and alumns of our MDACC Cancer Network at #ASCO25 at our MD Anderson Cancer Center Booth at the annual ASCO meeting this year !!!

Come join us at 8am on Monday June 2 for a great educational session on advocacy! #ASCO25

#ASCO25 #Plenary #VERIFY trial presented by Dr. Andrew Kuykendall. #Rusfertide (hepcidin mimetic); restores iron homeostasis in the bone marrow which is impaired in #PV. Study meets its primary endpoint: reduction in phlebotomies. Well tolerated with no significant AE’s.

Nice to catch up with Vivek Subbiah, MD Steve Strickland Krish Patel & Hans Lee at #ASCO25 ! Naveen Pemmaraju, MD

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL #ASCO25 | ASCO

So proud of co-fellow Marija Sullivan, MD on a great presentation on real world implementation of Oncotype results. MD Anderson Cancer Center #ASCO25 #endcancer

👉👉👉So happy to catch up with my childhood family friend & ASCO superstar Dr Neelima Denduluri at #ASCO25 !! 🙏

Fertility preservation is a key concern for many women with cancer, yet it’s often overlooked. Dr. Terri Woodard highlights the need to address this early in treatment planning. Timely referral to a reproductive specialist can ease distress and expand options. #ASCO25 #EndCancer

Dr. Eric Singhi shares his excitement about the lung cancer research being presented at #ASCO25. Hear how this year’s meeting highlights the continued momentum in advancing the field and improving patient outcomes. #EndCancer Eric K. Singhi, MD

"I experienced firsthand the consuming worry that occurs from the moment cancer is suspected until you have an answer," writes Ruben A. Mesa, MD/Atrium Health. "I was lucky—I got an answer in under 48 hours. It was the longest 48 hours of my life." cancerletter.com/trials-and-tri…

👉👉👉Important presentation by Ruben A. Mesa, MD for #MPNSM field at #ASCO25 presenting the #SURPASS-ET study : Positive study for #RopegIFN for patients with high-risk randomized ph3 vs Anagrelide for patients intoler/resistant to prior HU in Essential Thrombocytosis | Lucia Masarova, MD ASCO

#ASCO25 Prof Andreas Hochhaus | #ASC4START #asciminib met its primary endpoint vs nilotinib in newly dx patients with CML #leusm ASCO

New data from the CADENZA study shows pivekimab sunirine (PVEK) led to a 70% CR + CRc rate in frontline BPDCN with a manageable safety profile. Presented by Dr. Naveen Pemmarju at #ASCO25. #EndCancer bit.ly/45E62i9 Naveen Pemmaraju, MD

Great talk given by Naveen Pemmaraju, MD on CADENZA on BPDCN. Phase 2 CADENZA trial (NCT03150693), a pivotal study of pivekimab sunirine (PVEK), a CD123-targeting antibody-drug conjugate, in frontline and relapsed/refractory (R/R) BPDCN. BPDCN is a rare, aggressive malignancy affecting

Naveen Pemmaraju, MD updating at #ASCO25 PVEK (CD123-ADC) in BPDCN - CADENZA study High & durable response in 1L (de novo and PCHM):CR+CRc= 70% PCHM did not impact OS in 1L Half of 1L who received PVEK subsequently got SCT Good response also for R/R patients Manageable safety profile